2 results
Approved WMOCompleted
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
Approved WMORecruiting
Using state of the art CMR imaging techniques, we will characterize ablation lesions in the early phase after pulmonary vein isolation, and relate findings to (1) the ablation scar at 3 months follow up and (2) atrial fibrillation-free survival at 1…